Chitinase-3-like protein 1 levels in bipolar disorder

Basit Öğe Kaydı
dc.authoridCaliskan, Ali Metehan/0000-0002-7347-7200
dc.contributor.authorSahin, Basak
dc.contributor.authorInanli, Ikbal
dc.contributor.authorCaliskan, Ali M.
dc.contributor.authorUysal, Sema
dc.date.accessioned2025-01-27T20:31:56Z
dc.date.available2025-01-27T20:31:56Z
dc.date.issued2019
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractObjectives: To evaluate the relationship between the expression level and biologic role of YKL-40 in bipolar disorder (BD). Methods: This case-control study was conducted in the Faculty of Medicine, Canakkale Onsekiz Mart University, Canakkale, Turkey in 2015. One hundred and four patients diagnosed as having bipolar disorder (DSM5 criteria), and 96 participants were included as healthy controls in this study. A human YKL-40 enzyme-linked immunosorbent assay (ELISA) kit was used to measure the serum YKL-40 levels. As independent variables, we collected data on C-reactive protein (CRP), demographic variables, and medications. Results: The mean YLK-40 levels for the BD was 2723.5 +/- 543.8 pg/ml and control groups was 2132.5 +/- 576.3 pg/ml (t=7.42, p<0.001). The mean CRP levels for the BD was 0.4 +/- 0.6 mg/dl and control groups was 0.4 +/- 0.7 mg/dl (t=0.02, p=0.985). The receiver operating characteristics (ROC) analysis revealed an area under the curve (AUC) of YKL-40 in the diagnosis of BD as 0.79 (95% confidence interval [CI]: 0.72-0.85) with a sensitivity of 82.7% and specificity of 68.1% at a cutoff level of 2307.1 pg/ml. The use of antidepressants, antipsychotics, mood modifiers, and the presence of any comorbidity was not related to the YKL-40 levels (p> 0.05). Conclusion: With acceptable sensitivity and specificity levels, the YKL-40 can be utilized as a marker in the diagnosis and follow-up of BD.
dc.identifier.doi10.15537/smj.2019.1.23396
dc.identifier.endpage32
dc.identifier.issn0379-5284
dc.identifier.issn1658-3175
dc.identifier.issue1
dc.identifier.pmid30617377
dc.identifier.scopus2-s2.0-85059927930
dc.identifier.scopusqualityQ2
dc.identifier.startpage26
dc.identifier.urihttps://doi.org/10.15537/smj.2019.1.23396
dc.identifier.urihttps://hdl.handle.net/20.500.12428/23310
dc.identifier.volume40
dc.identifier.wosWOS:000472227100003
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSaudi Med J
dc.relation.ispartofSaudi Medical Journal
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectGenome-Wide Association
dc.subjectHuman Cartilage Gp-39
dc.subjectMetabolic Syndrome
dc.subjectYkl-40 Expression
dc.subjectMember
dc.subjectReliability
dc.subjectPrevalence
dc.subjectValidity
dc.subjectSpectrum
dc.subjectMarkers
dc.titleChitinase-3-like protein 1 levels in bipolar disorder
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu